The U.S. Food and Drug Administration (FDA) has cleared NeuroOne’s OneRF Ablation System, a brain electrode-guided tool employed in neurosurgical procedures, including those for Parkinson’s disease, to capture electrical activity and selectively destroy nervous tissue within controlled temperature settings. The request was submitted through a 510(k) application, which…
News
People with Parkinson’s disease and their caregivers need more timely information on what palliative care services are available and how to access them, along with more of such services, according to a review of published studies. Palliative care refers to specialized medical care for people living with a serious…
Amneal Pharmaceuticals and Bial have entered into a licensing agreement giving Amneal exclusive rights to market and distribute Ongentys (opicapone) in the U.S. as an add-on treatment for people with Parkinson’s disease. Owned by Bial, Ongentys was approved by the U.S. Food and…
Researchers have developed a way to generate a family of nerve cells implicated in Parkinson’s disease in the lab using human stem cells, according to newly published research. These cells, found in a brain region called the locus coeruleus (LC), produce a signaling chemical called norepinephrine, or NE. While these…
Neurocrine Biosciences is opening two Phase 1 clinical trials in healthy adults to test two oral candidate muscarinic receptor agonists intended to treat Parkinson’s disease and other neurological conditions. Both investigational therapies — called NBI-1117569 and NBI-1117567 — were developed by Sosei Heptares, which licensed…
A neurologist and movement disorders specialist at the University of California, Los Angeles (UCLA), is working to develop a way to help Parkinson’s disease researchers better assess and recruit Black patients into clinical studies. If successful, the tool planned by Jennifer Adrissi could be adapted for use…
Members of the Support Group for Black Patients with Parkinson’s Disease took part in the Parkinson Council’s Walk to Stamp Out Parkinson’s event in November and raised more than $3,400, helping the Council to come within 70% of its $400,000 fundraising goal. The support group, which was launched in…
Alterity Therapeutics‘ ATH434 improved motor performance and overall function in non-human primates with induced Parkinson’s disease, according to data presented at the recent Future of Parkinson’s Disease Conference 2023. The investigational therapy is currently undergoing evaluation in an open-label biomarker study called ATH434-202 (NCT05864365), which has…
Phasing out fossil fuels could save an estimated 5.1 million lives each year worldwide by preventing deaths attributed to ambient air pollution, including those likely due to neurodegenerative diseases such as Parkinson’s, a study has found. Transitioning to clean, renewable energy sources is not only an effective intervention to…
The University of Buffalo (UB) now has a Parkinson Voice Project (PVP) SPEAK OUT! center, featuring its signature speech therapy program, which aims to help people with Parkinson’s disease — at no cost to them — maintain their voices, minimize any swallowing problems, and better communicate with,…
Recent Posts
- Lessons revealed in the quiet moments of Parkinson’s caregiving
- Gut immune cells may help Parkinson’s spread from the belly to the brain
- New delivery system guides curcumin to Parkinson’s-affected brain cells
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis